Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.

NCT07417631 · Active, not recruiting

Last updated 2026-05-28

This study tested whether a medication used for type 2 diabetes affects the risk of heart attack, stroke, or death in people with type 2 diabetes by analyzing existing health insurance records.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 30,000 people Planned (estimated).

Who can join Ages 50+ · all sexes

Timeline Started 2026-02 · est. completion 2026-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07417631 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

Dulaglutide Drug

Initiation of dulaglutide dispensing claim is used as the exposure.
Sitagliptin Drug

Initiation of sitagliptin dispensing claim is used as the reference.

Main thing measured	Composite of myocardial infarction, stroke, or all-cause mortality.
Sponsor	Brigham and Women's Hospital
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07417631 ↗